Patent details
EP2467372 Title: TREATMENT OF BDNF-RELATED DISORDERS USING LAQUINIMOD
Basic Information
- Publication number:
- EP2467372
- PCT Application Number:
- PCT/US/2010/002194
- Type:
- European Patent Granted for LU
- Legal Status:
- Lapsed
- Application number:
- EP108084427
- PCT Publication Number:
- WO/2011/019375
- First applicant's nationality:
- Translation Language:
- EPO Publication Language:
- English
- English Title of Invention:
- TREATMENT OF BDNF-RELATED DISORDERS USING LAQUINIMOD
- French Title of Invention:
- TRAITEMENT DE TROUBLES LIÉS AU FNDC AU MOYEN DE LAQUINIMOD
- German Title of Invention:
- BEHANDLUNG BDNF-ASSOZIIERTER ERKRANKUNGEN MIT LAQUINIMOD
- SPC Number:
Dates
- Filing date:
- 09/08/2010
- Grant date:
- 18/05/2016
- EP Publication Date:
- 18/05/2016
- PCT Publication Date:
- 17/02/2011
- Claims Translation Received Date:
- Translations Received Date (B1 EP Publication):
- Translations Received Date (B2 EP Publication):
- Translations Received Date (B3 EP Publication):
- Publication date:
- 27/06/2012
- EP B1 Publication Date:
- 18/05/2016
- EP B2 Publication Date:
- EP B3 Publication Date:
- Lapsed date:
- 09/08/2019
- Expiration date:
- 09/08/2030
- Renunciation date:
- Revocation date:
- Annulment date:
Owner
- From:
- 09/08/2010
- Name:
- Teva Pharmaceutical Industries Ltd.
- Address:
- 5 Basel Street P.O. Box 3190, 49131 Petah Tiqva, Israel (IL)
Agent
- Name:
- OFFICE FREYLINGER S.A.
- From:
- 03/08/2016
- Address:
- Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)
- To:
Inventor
- Name:
- HAYARDENY Liat
- Address:
- Israel (IL)
Priority
- Priority Number:
- 273920 P
- Priority Date:
- 10/08/2009
- Priority Country:
- United States (US)
Classification
- Main IPC Class:
- A61K 31/4704;
Annual Fees
- Annual Fee Due Date:
- Annual Fee Number:
- Expected Payer:
- Last Annual Fee Payment Date:
- 21/08/2018
- Last Annual Fee Paid Number:
- 9
- Last Annual Fee Paid Amount:
- 115 Euro
- Payer:
- DENNEMEYER & CO
| Filing date | Document type | Number of pages |
|---|